Vimarsana
Biggest News Aggregation in the World

Jo Dulay News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jo Dulay. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jo Dulay Today - Breaking & Trending Today

New Data for Genentech's Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided | National Business - Vimarsana News

New Data for Genentech's Ocrevus Show That After 10 Years of Treatment 77% of People With Relapsing Multiple Sclerosis Were Free From Disability Progression and 92% Continue to Walk Unaided | National Business

Published: October 12, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 12, 2023--

Source: joplinglobe.com
Related Topics:
South San FranciscoUnited StatesSan FranciscoBruno EschliJo DulayStephen HauserLoren KalmMichelle MccourtUniversity Of CaliforniaResearch In Multiple SclerosisRoche GroupScientific Steering CommitteeWeill Institute For NeurosciencesAmericas CommitteesMultiple SclerosisWeill InstituteImportant SafetyMultifocal LeukoencephalopathyOcrevus PregnancyImportant Safety InformationPrescribing InformationMedia ContactBusiness WireNational Business
First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech's Ocrevus Effectively Manages Disease Activity | Region - Vimarsana News

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech's Ocrevus Effectively Manages Disease Activity | Region

Published: October 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--

Source: eagletribune.com
Related Topics:
South San FranciscoUnited StatesPuerto RicoMitzi Joi WilliamsBruno EschliLoren KalmMichelle MccourtJo DulayQuita HighsmithRoche GroupResearch In Multiple SclerosisJoi Life Wellness Ms CenterAmericas CommitteesMultiple SclerosisJoi Life WellnessImportant SafetyMultifocal LeukoencephalopathyOcrevus PregnancyImportant Safety InformationPrescribing InformationBased EstimatesMedia ContactBusiness Wire
Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions | Business - Vimarsana News

Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions | Business

Published: October 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--

Source: valdostadailytimes.com
Related Topics:
South San FranciscoUnited StatesBruno EschliLoren KalmJo DulayLevi GarrawayMichelle MccourtResearch In Multiple SclerosisRoche GroupGlobal Product DevelopmentAmericas CommitteesMultiple SclerosisGlobal ProductPeak OcrevusHalozyme Therapeutic EnhanzeImportant SafetyMultifocal LeukoencephalopathyOcrevus PregnancyImportant Safety InformationPrescribing InformationMedia ContactBusiness Wire
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strengt - Vimarsana News

Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strengt

Published: October 2, 2023

–– Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented–– 10-year Ocrevus efficacy and safety data show significant benefit in slowing long-term disability progression and consistent lo...

Source: pharmiweb.com
Related Topics:
South San FranciscoUnited StatesJo DulayBruno EschliLevi GarrawayMichelle MccourtLoren KalmResearch In Multiple SclerosisRoche GroupGlobal Product DevelopmentAdditional OcrevusAmericas CommitteesMultiple SclerosisGlobal ProductLate BreakingPoster Presentation SessionScientific SessionGerman NeurotransdataMyasthenia GravisAutoimmune EncephalitisBreakthrough Therapy DesignationImportant SafetyMultifocal Leukoencephalopathy
Positive Phase III Results for Genentech's Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis - Vimarsana News

Positive Phase III Results for Genentech's Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis

Published: July 13, 2023

–– Phase III OCARINA II trial met primary and secondary endpoints–– Ocrevus 10-minute injection has the potential to further improve the treatment experience and expand Ocrevus® usage in MS centers with IV capacity limitations or without IV infrastructure–– Ocrevus remains the first and only therapy approved for bot...

Source: pharmiweb.com
Related Topics:
South San FranciscoUnited StatesLoren KalmLevi GarrawayMichelle MccourtJo DulayBruno EschliRoche GroupGlobal Product DevelopmentGlobal ProductHalozyme Therapeutic EnhanzeImportant SafetyMultifocal LeukoencephalopathyOcrevus PregnancyPrescribing InformationManag Care Spec